ChartRow logo
Data provided bySource: Twelve Data
RPRX
$68.68+0.23%
as of close, Nov 17, 2026
☾ AH $68.68 +0.23%
Share this page

RPRX financial statements

The full income statement, balance sheet, and cash-flow statement for Royalty Pharma plc (RPRX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Financial overview#

Revenue

5Y CAGR +2.3%5Y CAGR +2.3%YoY +13.3%
$2.6B TTM$690.1M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR −0.5%5Y CAGR −0.5%YoY −3.8%
$1.5B TTM$410.8M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR −4.6%5Y CAGR −4.6%YoY −49.1%
$672.5M TTM$144.7M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR +6.2%5Y CAGR +6.2%YoY −51.5%
$1.78 FY25$0.32 Q3 '26
FY20FY21FY22FY23FY24FY25
Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating cash flow

5Y CAGR +4.1%5Y CAGR +4.1%YoY −2.4%
$3B TTM$686.1M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Shares (diluted)

5Y +50.3%5Y +50.3%YoY −0.5%
557.1M TTM557M Q3 '26
FY20FY21FY22FY23FY24FY25TTM
Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Dividend per share

YoY +6.8%
$0.92 TTM$0.23 Q3 '26
FY20FY21FY22FY23FY24FY25TTM
Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Every RPRX chart on Trends →

Shares outstanding (point-in-time)

2024-09 589.2M2024-12 576.5M2025-03 562.2M2025-06 583.2M2025-09 577.2M2025-12 576.9M2026-03 575.8M2026-06 575.0M2026-09 573.6M-2.6% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeFiguresAs-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Revenue2.38B+5.1%2.26B-3.9%2.35B+5.2%2.24B-2.3%2.29B+7.9%
Research & development452M+22500.0%2.00M-96.2%52.0M-70.6%177M-11.5%200M+661.1%
Selling, general & administrative573M+142.3%237M-5.2%250M+9.9%227M+24.3%183M+0.6%
General & administrative573M+142.3%237M-5.2%250M+9.9%227M+24.3%183M+0.6%
Amortization of intangibles—0.000.00-100.0%5.67M-75.3%23.0M-0.3%
Provision for credit losses
————453M+96.2%
Operating income1.56B+20.7%1.29B-13.4%1.49B+385.9%307M-78.5%1.43B-10.3%
Interest expense308M+36.4%226M+20.5%187M-0.4%188M+13.1%166M+5.8%
Other non-operating income-14.3M-839.1%-1.53M+93.0%-21.7M-47.3%-14.8M-159.9%-5.68M+82.7%
Equity-method income29.1M-1.8%29.6M+2.5%28.9M+421.9%-8.97M+54.0%-19.5M-143.8%
Gain (loss) on equity securities-21.9M-155.3%39.5M-54.6%87.1M+360.6%-33.4M+30.4%-48.1M-119.5%
Pre-tax income1.32B-0.5%1.33B-21.7%1.70B+639.0%230M-81.5%1.24B-27.1%
Income tax0.000.000.000.000.00
771M-10.2%859M-24.3%1.13B+2549.5%42.8M-93.1%620M-36.4%
Net income to non-controlling interest553M+17.3%472M-16.5%565M+201.9%187M-69.9%621M-14.5%
Net income to common771M-10.2%859M-24.3%1.13B+2549.5%42.8M-93.1%620M+25.1%
$1.78-6.8%$1.91-24.5%$2.53+2430.0%$0.10-93.3%$1.49+12.9%
EPS (basic)$1.79-6.8%$1.92-24.4%$2.54+2440.0%$0.10-93.3%$1.49+12.9%
Weighted-avg shares (basic)430M-4.1%448M+0.1%448M+2.2%438M+5.6%415M+10.5%
Weighted-avg shares (diluted)564M-5.0%594M-1.5%603M+37.7%438M+5.6%415M+10.5%
Dividends per share—$0.84+5.0%$0.80+5.3%$0.76+11.8%$0.68+126.7%
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
1.53B-15.2%1.80B+41.4%1.27B-50.1%2.55B-11.2%2.88B+6.7%
Cash & equivalents619M-33.4%929M+94.8%477M-72.1%1.71B+11.0%1.54B+52.8%
Other current assets6.89M+64.6%4.19M-76.8%18.0M-80.1%90.5M+1265.1%6.63M-22.9%
19.6B+7.7%18.2B+11.2%16.4B-2.6%16.8B-4.0%17.5B+9.3%
Goodwill925M0.00———
Intangible assets———0.00-100.0%5.67M-80.2%
Other non-current assets79.3M+136.5%33.5M+414.2%6.52M-78.0%29.6M+614.8%4.14M-58.5%
636M-49.2%1.25B+676.8%161M-86.2%1.17B+581.3%171M-44.4%
Accrued liabilities19.4M+45.1%13.4M-11.8%15.2M+91.8%7.91M+40.7%5.62M-47.8%
Short-term & current debt380M-61.9%998M0.00-100.0%998M0.00
Other current liabilities53.2M-22.5%68.6M+503.1%11.4M-8.3%12.4M0.00-100.0%
9.91B+25.7%7.88B+25.1%6.30B-13.6%7.29B+0.3%7.27B+18.7%
Long-term debt8.57B+29.6%6.61B+7.8%6.14B+0.3%6.12B-13.8%7.10B+22.0%
Operating lease liability (total)
19.3M————
Other non-current liabilities121M+900.4%12.1M+1242.2%900K-64.0%2.50M0.00
6.48B-6.8%6.95B+6.4%6.53B+16.0%5.63B-2.6%5.78B+19.9%
Additional paid-in capital4.12B+0.5%4.10B+2.3%4.01B+9.4%3.67B+4.5%3.51B+22.4%
Retained earnings2.36B-17.2%2.85B+13.0%2.52B+28.1%1.96B-12.9%2.26B+17.4%
Treasury stock2.61M-1.9%2.66M+1.3%2.63M-6.3%2.81M+3.4%2.71M+17.2%
Accumulated other comprehensive income———0.00-100.0%16.5M-52.1%
Non-controlling interest3.24B-4.6%3.40B-4.6%3.56B-8.7%3.90B-12.9%4.47B-11.9%
Total equity incl. non-controlling9.71B-6.1%10.3B+2.6%10.1B+5.9%9.53B-7.1%10.2B+3.6%
Total liabilities & equity19.6B+7.7%18.2B+11.2%16.4B-2.6%16.8B-4.0%17.5B+9.3%
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
2.49B-10.1%2.77B-7.3%2.99B+39.4%2.14B+6.3%2.02B-0.8%
Depreciation & amortization3.85M0.000.00——
Intangible amortization—0.000.00-100.0%5.67M-75.3%23.0M-0.3%
Share-based compensation290M+12267.5%2.34M-0.6%2.36M+8.6%2.17M-11.2%2.44M-55.0%
-1.61B+39.7%-2.68B-29.2%-2.07B-101.4%-1.03B+45.0%-1.87B+32.2%
Acquisitions74.4M0.000.000.000.00
Other investing activities8.95M+538.7%-2.04M-200.0%2.04M0.000.00
-1.19B-428.4%361M+116.8%-2.15B-127.4%-945M-345.3%385M-74.1%
Long-term debt issued——0.000.00-100.0%1.27B-89.3%
Long-term debt repaid0.000.00—0.000.00-100.0%
Common stock issued0.000.000.000.000.00
Common stock repurchased1.23B+434.5%230M-24.6%305M0.000.00
Other financing activities-1.79M+80.2%-9.03M0.000.00—
Net change in cash-310M-168.7%452M+136.6%-1.23B-827.0%170M-68.1%532M-30.2%
Interest paid276M+73.1%160M-5.7%169M-0.6%170M+30.4%130M+26.4%
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Market cap22.3B+51.6%14.7B-12.4%16.8B-30.1%24.0B-0.8%24.2B-20.4%
P/E28.9×+68.9%17.1×-81.2%91.0×+92.2%47.3×+21.3%39.0×+25.3%
P/S9.4×+44.3%6.5×-10.0%7.2×-32.4%10.7×+1.0%10.6×-26.2%
P/B3.4×+62.6%2.1×-22.6%2.7×-29.9%3.9×-6.9%4.2×-33.6%
Earnings yield3.5%-40.8%5.8%+431.6%1.1%-48.0%2.1%-17.5%2.6%-20.2%
Dividend yield—3.3%+15.6%2.8%+48.1%1.9%+12.7%1.7%+184.7%
Source filing10-K10-K10-K10-K10-K
Fiscal yearCEOTotal, as reportedActually paidOther executives, average$100 in the stock$100 in peers
FY2025Mr. Legorreta$937.5K$82.5M$1.3M$85.11$206.25
FY2024Mr. Legorreta—$191.3M$1.3M$57.12$169.75
FY2023Mr. Legorreta—$26.8M$4.6M$60.60$152.01
FY2022Mr. Legorreta—$45.8M$4.3M$81.84$141.19
FY2021Mr. Legorreta—$57M$3.8M$80.98$127.61
FY2020Mr.Legorreta—$51.5M$3.5M——

From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.

About this data

Source: RPRX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all RPRX filings on SEC EDGAR → Not investment advice.